Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Total Current Liabilities (2016 - 2025)

Ani Pharmaceuticals (ANIP) has disclosed Total Current Liabilities for 16 consecutive years, with $278.1 million as the latest value for Q4 2025.

  • Quarterly Total Current Liabilities rose 43.02% to $278.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $278.1 million through Dec 2025, up 43.02% year-over-year, with the annual reading at $278.1 million for FY2025, 43.02% up from the prior year.
  • Total Current Liabilities hit $278.1 million in Q4 2025 for Ani Pharmaceuticals, up from $270.6 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $278.1 million in Q4 2025 to a low of $79.5 million in Q1 2022.
  • Historically, Total Current Liabilities has averaged $143.9 million across 5 years, with a median of $130.1 million in 2023.
  • Biggest five-year swings in Total Current Liabilities: dropped 3.91% in 2022 and later skyrocketed 69.19% in 2025.
  • Year by year, Total Current Liabilities stood at $87.5 million in 2021, then rose by 13.6% to $99.4 million in 2022, then surged by 46.3% to $145.5 million in 2023, then skyrocketed by 33.67% to $194.5 million in 2024, then surged by 43.02% to $278.1 million in 2025.
  • Business Quant data shows Total Current Liabilities for ANIP at $278.1 million in Q4 2025, $270.6 million in Q3 2025, and $236.8 million in Q2 2025.